AVITA Medical Issues 119,375 Shares To Perceptive And 148,158 To OrbiMed Through Cashless Exercises
Additional borrowing activated one creditor's stock rights, while another exercised a warrant tied to a separate credit agreement.
AVITA Medical, which sells products to treat acute wounds, issued 119,375 shares to creditor Perceptive and 148,158 to creditor group OrbiMed on Wednesday through cashless warrant exercises. The company reported the transactions in an SEC 8-K filed Friday; additional borrowing had activated Perceptive's previously disclosed right to obtain stock.
Shares Paid The Exercise Price
The creditors used warrants — rights to obtain company stock — connected to AVITA's borrowing agreements. With a cashless exercise, AVITA withheld part of the stock covered by each warrant to cover the exercise price and delivered the balance to the creditor.
Perceptive Credit Holdings V's warrant covered up to 150,000 common shares. AVITA withheld 30,625 shares and issued 119,375 to Perceptive.
OrbiMed's warrant covered up to 409,661 common shares. AVITA withheld 261,503 shares and delivered 148,158 to the group, comprising OrbiMed Royalty & Credit Opportunities IV and OrbiMed Royalty & Credit Opportunities IV Offshore.
Borrowing Activated Perceptive's Rights
AVITA borrowed additional funds on November 3 under its Perceptive credit agreement, satisfying the condition that made the warrant exercisable. That agreement dates to January 13, 2026, and AVITA issued the warrant on June 5, 2026.
OrbiMed's stock rights came from a separate credit agreement with an OrbiMed affiliate dated October 18, 2023. AVITA issued OrbiMed's warrant on that same date.
Both warrants were previously disclosed. Wednesday's exercises turned those rights into issued common stock, with each creditor receiving the shares left after AVITA covered the exercise price.
RECELL Anchors The Wound Business
AVITA serves U.S. burn, trauma and surgical centers. Its main product, RECELL, is an FDA-approved device clinicians use at the point of care to prepare a spray containing a patient's own skin cells.
The company also sells PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. AVITA makes RECELL and PermeaDerm at its Ventura, California plant.
Outside the U.S., AVITA sells through third-party distributors. RECELL has approvals or registrations in Australia, Europe and Japan.
For existing RCEL holders, the exercises added common shares to the outstanding stock while giving the creditors ownership through their contractual stock rights.
Sources
- 8-K Filing — AVITA Medical, Inc. (RCEL) — SEC EDGAR